A detailed history of Woodline Partners LP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 900,421 shares of EDIT stock, worth $1.21 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
900,421
Previous 970,491 7.22%
Holding current value
$1.21 Million
Previous $4.53 Million 32.26%
% of portfolio
0.03%
Previous 0.05%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$3.39 - $5.96 $237,537 - $417,617
-70,070 Reduced 7.22%
900,421 $3.07 Million
Q2 2024

Aug 14, 2024

BUY
$4.67 - $7.28 $352,542 - $549,574
75,491 Added 8.43%
970,491 $4.53 Million
Q1 2024

May 15, 2024

SELL
$7.03 - $11.07 $2,819 - $4,439
-401 Reduced 0.04%
895,000 $6.64 Million
Q4 2023

Feb 14, 2024

SELL
$6.25 - $11.11 $14.8 Million - $26.3 Million
-2,364,309 Reduced 72.53%
895,401 $9.07 Million
Q3 2023

Nov 14, 2023

BUY
$6.92 - $9.31 $3.53 Million - $4.75 Million
510,405 Added 18.56%
3,259,710 $25.4 Million
Q2 2023

Aug 14, 2023

BUY
$6.36 - $11.47 $653,076 - $1.18 Million
102,685 Added 3.88%
2,749,305 $22.6 Million
Q1 2023

May 15, 2023

BUY
$7.03 - $11.53 $3.99 Million - $6.55 Million
567,872 Added 27.32%
2,646,620 $19.2 Million
Q4 2022

Feb 14, 2023

BUY
$8.32 - $13.21 $17.3 Million - $27.5 Million
2,078,748 New
2,078,748 $18.4 Million
Q2 2022

Aug 15, 2022

BUY
$9.99 - $21.35 $9.93 Million - $21.2 Million
994,020 Added 4346.2%
1,016,891 $12 Million
Q1 2022

May 16, 2022

BUY
$14.08 - $27.63 $322,023 - $631,925
22,871 New
22,871 $435,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $92.1M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.